Desloratadine ratiopharm

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
24-06-2022
Karakteristik produk Karakteristik produk (SPC)
24-06-2022

Bahan aktif:

desloratadine

Tersedia dari:

Ratiopharm GmbH

Kode ATC:

R06AX27

INN (Nama Internasional):

desloratadine

Kelompok Terapi:

Antihistamines for systemic use,

Area terapi:

Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal

Indikasi Terapi:

Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician

Ringkasan produk:

Revision: 12

Status otorisasi:

Authorised

Tanggal Otorisasi:

2012-01-13

Selebaran informasi

                                19
B. PACKAGE LEAFLET
20
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DESLORATADINE RATIOPHARM 5 MG FILM-COATED TABLETS
desloratadine
For adults
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist has told
you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
You must talk to a doctor if you do not feel better or if you feel
worse after 7 days.
WHAT IS IN THIS LEAFLET
1.
What Desloratadine ratiopharm is and what it is used for
2.
What you need to know before you take Desloratadine ratiopharm
3.
How to take Desloratadine ratiopharm
4.
Possible side effects
5.
How to store Desloratadine ratiopharm
6.
Contents of the pack and other information
1.
WHAT DESLORATADINE RATIOPHARM IS AND WHAT IT IS USED FOR
WHAT DESLORATADINE RATIOPHARM IS
Desloratadine ratiopharm contains desloratadine which is an
antihistamine.
HOW DESLORATADINE RATIOPHARM WORKS
Desloratadine ratiopharm is an antiallergy medicine that does not make
you drowsy. It helps control
your allergic reaction and its symptoms.
WHEN DESLORATADINE RATIOPHARM SHOULD BE USED
Desloratadine ratiopharm relieves symptoms associated with allergic
rhinitis (inflammation of the
nasal passages caused by an allergy, for example, hay fever or allergy
to dust mites) in adults. These
symptoms include sneezing, runny or itchy nose, itchy palate, and
itchy, red or watery eyes.
Desloratadine ratiopharm is also used to relieve the symptoms
associated with chronic idiopathic
urticaria (a skin condition with unknown cause), initially diagnosed
by your doctor. These symptoms
include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
You
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Desloratadine ratiopharm 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect:
Each tablet contains 14.25 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Round, biconvex, blue film-coated tablets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Desloratadine ratiopharm is indicated in adults for the relief of
symptoms associated with:
-
allergic rhinitis (see section 5.1)
-
chronic idiopathic urticaria as initially diagnosed by a physician
(see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is one tablet once a day.
Duration of treatment
The duration of treatment depends on the type, duration and course of
symptoms.
If symptoms persist for more than 7 days or deteriorate, patients
should seek medical advice in order
to minimise the risk of masking an underlying disease.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
For chronic idiopathic urticaria the symptoms may persist more than 6
weeks it is characterised by
recurrent episodes and continued treatment may be necessary.
_Paediatric population _
Desloratadine ratiopharm is not recommended for use in children and
adolescents below 18 years of
age.
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents
12 through 17 years of age (see sections 4.8 and 5.1).
3
The safety and efficacy of Desloratadine
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 24-06-2022
Karakteristik produk Karakteristik produk Bulgar 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 03-02-2021
Selebaran informasi Selebaran informasi Spanyol 24-06-2022
Karakteristik produk Karakteristik produk Spanyol 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 03-02-2021
Selebaran informasi Selebaran informasi Cheska 24-06-2022
Karakteristik produk Karakteristik produk Cheska 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 03-02-2021
Selebaran informasi Selebaran informasi Dansk 24-06-2022
Karakteristik produk Karakteristik produk Dansk 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 03-02-2021
Selebaran informasi Selebaran informasi Jerman 24-06-2022
Karakteristik produk Karakteristik produk Jerman 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 03-02-2021
Selebaran informasi Selebaran informasi Esti 24-06-2022
Karakteristik produk Karakteristik produk Esti 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 03-02-2021
Selebaran informasi Selebaran informasi Yunani 24-06-2022
Karakteristik produk Karakteristik produk Yunani 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 03-02-2021
Selebaran informasi Selebaran informasi Prancis 24-06-2022
Karakteristik produk Karakteristik produk Prancis 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 03-02-2021
Selebaran informasi Selebaran informasi Italia 24-06-2022
Karakteristik produk Karakteristik produk Italia 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 03-02-2021
Selebaran informasi Selebaran informasi Latvi 24-06-2022
Karakteristik produk Karakteristik produk Latvi 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 03-02-2021
Selebaran informasi Selebaran informasi Lituavi 24-06-2022
Karakteristik produk Karakteristik produk Lituavi 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 03-02-2021
Selebaran informasi Selebaran informasi Hungaria 24-06-2022
Karakteristik produk Karakteristik produk Hungaria 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 03-02-2021
Selebaran informasi Selebaran informasi Malta 24-06-2022
Karakteristik produk Karakteristik produk Malta 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 03-02-2021
Selebaran informasi Selebaran informasi Belanda 24-06-2022
Karakteristik produk Karakteristik produk Belanda 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 03-02-2021
Selebaran informasi Selebaran informasi Polski 24-06-2022
Karakteristik produk Karakteristik produk Polski 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 03-02-2021
Selebaran informasi Selebaran informasi Portugis 24-06-2022
Karakteristik produk Karakteristik produk Portugis 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 03-02-2021
Selebaran informasi Selebaran informasi Rumania 24-06-2022
Karakteristik produk Karakteristik produk Rumania 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 03-02-2021
Selebaran informasi Selebaran informasi Slovak 24-06-2022
Karakteristik produk Karakteristik produk Slovak 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 03-02-2021
Selebaran informasi Selebaran informasi Sloven 24-06-2022
Karakteristik produk Karakteristik produk Sloven 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 03-02-2021
Selebaran informasi Selebaran informasi Suomi 24-06-2022
Karakteristik produk Karakteristik produk Suomi 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 03-02-2021
Selebaran informasi Selebaran informasi Swedia 24-06-2022
Karakteristik produk Karakteristik produk Swedia 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 03-02-2021
Selebaran informasi Selebaran informasi Norwegia 24-06-2022
Karakteristik produk Karakteristik produk Norwegia 24-06-2022
Selebaran informasi Selebaran informasi Islandia 24-06-2022
Karakteristik produk Karakteristik produk Islandia 24-06-2022
Selebaran informasi Selebaran informasi Kroasia 24-06-2022
Karakteristik produk Karakteristik produk Kroasia 24-06-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 03-02-2021

Peringatan pencarian terkait dengan produk ini